|
Breath test for lung cancer | Menssana Products
|
Every year in the U.S.A., 99,000 men and 78,000 women develop lung cancer, and only 14% of them are still alive five years later. Fortunately, early detection and treatment can reduce the number of deaths. Clinical studies at Menssana Research, Inc. have shown that breath biomarkers accurately identify lung cancer, and this has been confirmed in a blinded replicated study. Publications (PDF Document) Blinded Validation of Breath Biomarkers of Lung Cancer, a Potential Ancillary to Chest CT Screening. Phillips M, Bauer TL, Cataneo RN, Lebauer C, Mundada M, Pass HI, Ramakrishna N, Rom WN, Vallieres EPLoS ONE (23 Dec. 2015)(PDF Document) Volatile Organic Compounds of Lung Cancer and Possible Biochemical Pathways. Hakim M, Broza YY, Barash O, Peled N, Phillips M, Amann A, Haick HChemical Reviews, 10.1021/cr300174a (Sep. 19, 2012)(PDF Document) Detection of Lung Cancer Using Weighted Digital Analysis of Breath Biomarkers. Phillips M, Altorki N, Austin JHM, Cameron RB, Cataneo RN, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, Rom WN, Schmitt P, Wai JClinica Chimica Acta ref. CCA10989 (May 31, 2008)(PDF Document) Prediction of lung cancer using volatile biomarkers in breath. Phillips M, Altorki N, Austin JHM, Cameron RB, Cataneo RN, Greenberg J, Robert Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A, Rom WN, and Schmitt PCancer Biomarkers (2007); 3: 95-109.(PDF document) Detection of lung cancer with volatile markers in the breath. Phillips M, Cataneo RN, Cummin ARC, Gagliardi AJ, Gleeson K, Greenberg J, Maxfield RA, Rom WNChest (2003); 123: 2115-2123(PDF document) Volatile organic compounds in breath as markers of lung cancer: a cross-sectional study. Phillips M, Gleeson K, Hughes JMB, Greenberg J, Cataneo RN, Baker L and McVay WPLancet (1999); 353: 1930-33. Commentary Lancet (1999); 353: 1897-1898 |
|